MOH Research Note — Medical Costs Stay Unresolved
Molina's raised outlook faces a 92.2% medical-cost ratio, a 57% ACA membership decline and weak price structure.
Research Notes
ASML Research Note — Cycle Still Needs Bookings Proof
ASML’s Q2 revenue rose 11% and new-system shipments rose 28%, but missing net bookings and weak price structure leave the cycle unconfirmed.
MS Research Note — Results Lead the Tape
Morgan Stanley’s record quarter strengthens the operating case, while sector lag and an unresolved Wealth Management question raise the proof bar.
UNH Research Note — Repair Needs More Proof
UnitedHealth improved Medicare cost evidence in July, but commercial pressure and a broader federal inquiry keep the repair incomplete.
QQQ Research Note — Long Trend, Narrow Leadership
QQQ held its long-term trend, but narrow breadth, technology weakness and rising yields leave the August evidence window unusually important.
JPM Research Note — Record Quarter, Higher Bar
JPMorgan’s record quarter supports the operating case, but rates, credit and a premium valuation leave the next evidence unusually important.
NVDA Research Note — Proof Returns to Center Stage
NVIDIA’s growth and margins remain exceptional, but July’s break below the 200-day average leaves customer budgets and earnings at center stage.
BIVI Research Note — Evidence Before the Headline
BioViespeed fell to $20.06, while negative gross margin and a larger share count leave the recovery thesis dependent on fresh factory evidence.
VICI Research Note — Guidance Rises, Shares Fall
VICI raised guidance as its shares fell 3.02%; rates, funding costs and concentrated tenant exposure now put the valuation discount to a harder test.
WULF Research Note — Clearances Do Not Close the Gap
WULF’s clearances matter, but the cash bridge to a second-half 2027 revenue start remains the central question.